Euroopa Liit -
eesti -
EMA (European Medicines Agency)
ngenla
pfizer europe ma eeig - somatrogon - growth and development - hÜpofÜÜsi ja hÜpotaalamuse hormoonid ja nende analoogid - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
Eesti -
eesti -
Ravimiamet
penthrox inhalatsiooniaur, vedelik
medical developments ned b.v. - metoksüfluraan - inhalatsiooniaur, vedelik - 99,9% w/w 3ml 10tk
Eesti -
eesti -
Ravimiamet
tmc 207 tablett
johnson&johnson preclinical development - bedakviliin - tablett - 100mg 28tk
Eesti -
eesti -
Ravimiamet
pevonedistat (tak-924/mln4924) infusioonilahuse kontsentraat
takeda development center americas, inc. - pevonedistaat - infusioonilahuse kontsentraat - 10mg 1ml 5ml 1tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
Eesti -
eesti -
Adama
kantik®
adama - emulsioonikontsentraat - fenpropidiin + prokloraas + tebukonasool - fungitsiidid